文献速递毛发、甲与色素性疾病

光疗治疗白癜风:系统评价与荟萃分析

Phototherapy for Vitiligo: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2017-01-01

该系统评价与荟萃分析纳入35项前瞻性研究共1428例泛发性白癜风患者,评估NBUVB和PUVA光疗的复色反应。结果显示NBUVB治疗12个月时至少轻度反应达75.0%,明显反应达35.7%;PUVA治疗12个月至少轻度反应为61.6%。面部和颈部反应最佳,手足无显著反应。

要点

  • NBUVB治疗12个月至少轻度反应率为75.0%,明显反应率为35.7%。
  • 光疗疗程应延长,面部和颈部复色反应最佳,手足无反应。
  • PUVA治疗12个月至少轻度反应率为61.6%。

核心结论

  • 应鼓励长期光疗以提高白癜风治疗反应,面部和颈部预期反应最佳。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、EMBASE和Cochrane图书馆至2016年1月26日的前瞻性研究。
  • 最终纳入35项研究,共1428例泛发性白癜风患者,其中29项研究1201例接受NBUVB,9项研究227例接受PUVA。

主要发现

  • NBUVB治疗3个月、6个月、12个月至少轻度反应率分别为62.1%、74.2%、75.0%。
  • NBUVB治疗3个月、6个月、12个月明显反应率分别为13.0%、19.2%、35.7%。
  • PUVA治疗6个月和12个月至少轻度反应率分别为51.4%和61.6%。
  • NBUVB治疗至少6个月后,面部和颈部明显反应率为44.2%,躯干为26.1%,四肢为17.3%,手足为0%。

关键数值与推荐

  • 反应评估采用四分位量表:至少轻度(≥25%)、至少中度(≥50%)、明显(≥75%)。
  • NBUVB组12个月至少轻度反应率75.0%(95% CI,60.9%-89.2%),明显反应率35.7%(95% CI,21.5%-49.9%)。
  • PUVA组12个月至少轻度反应率61.6%(95% CI,20.2%-100%)。

临床怎么用

  • 临床应鼓励白癜风患者坚持长期光疗,尤其面部和颈部皮损。
  • 对手足部位光疗反应差,需设定合理预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: References to the expected treatment response to phototherapy would be helpful in the management of vitiligo because phototherapy requires long treatment durations over several months. OBJECTIVE: To estimate the treatment response of vitiligo to phototherapy. DATA SOURCES: A comprehensive database search of MEDLINE, EMBASE, and the Cochrane library from inception to January 26, 2016, was performed for all prospective studies. The main keywords used were vitiligo, phototherapy, psoralen, PUVA, ultraviolet, NBUVB, and narrowband. STUDY SELECTION: All prospective studies reporting phototherapy outcome for at least 10 participants with generalized vitiligo were included. Of 319 studies initially identified, the full texts of 141 studies were assessed for eligibility, and 35 were finally included in the analysis. Of these, 29 studies included 1201 patients undergoing narrowband UV-B (NBUVB) phototherapy, and 9 included 227 patients undergoing psoralen-UV-A (PUVA) phototherapy. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted the following data: study design, number and characteristics of the participants, phototherapy protocol, and rate of repigmentation based on the quartile scale. Single-arm meta-analyses were performed for the NBUVB and PUVA groups. Sample size-weighted means were calculated using a random-effects model for the repigmentation rates of the included studies. MAIN OUTCOMES AND MEASURES: The primary outcomes were at least mild (≥25%), at least moderate (≥50%), and marked (≥75%) responses on a quartile scale. Response rates were calculated as the number of participants who showed the corresponding repigmentation divided by the number of all participants enrolled in the individual studies. RESULTS: The meta-analysis included 35 unique studies (1428 unique patients). For NBUVB phototherapy, an at least mild response occurred in 62.1% (95% CI, 46.9%-77.3%) of 130 patients in 3 studies at 3 months, 74.2% (95% CI, 68.5%-79.8%) of 232 patients in 11 studies at 6 months, and 75.0% (95% CI, 60.9%-89.2%) of 512 patients in 8 studies at 12 months. A marked response was achieved in 13.0% (95% CI, 2.1%-23.9%) of 106 patients in 2 studies at 3 months, 19.2% (95% CI, 11.4%-27.0%) of 266 patients in 13 studies at 6 months, and 35.7% (95% CI, 21.5%-49.9%) of 540 patients in 9 studies at 12 months. For PUVA phototherapy, an at least mild response occurred in 51.4% (95% CI, 28.1%-74.7%) of 103 patients in 4 studies at 6 months and 61.6% (95% CI, 20.2%-100%) of 72 patients in 3 studies at 12 months. In the subgroup analyses, marked responses were achieved on the face and neck in 44.2% (95% CI, 24.2%-64.2%), on the trunk in 26.1% (95% CI, 8.7%-43.5%), on the extremities in 17.3% (95% CI, 8.2%-26.5%), and on the hands and feet in none after at least 6 months of NBUVB phototherapy. CONCLUSIONS AND RELEVANCE: Long-duration phototherapy should be encouraged to enhance the treatment response in vitiligo. The greatest response is anticipated on the face and neck.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Bae JM, Jung HM, Hong BY, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017. PMID: 28355423. doi:10.1001/jamadermatol.2017.0002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。